• English

    Google Translate Disclaimer

    The Maryland Department of Information Technology (“DoIT”) offers translations of the content through Google Translate. Because Google Translate is an external website, DoIT does not control the quality or accuracy of translated content. All DoIT content is filtered through Google Translate which may result in unexpected and unpredictable degradation of portions of text, images and the general appearance on translated pages. Google Translate may maintain unique privacy and use policies. These policies are not controlled by DoIT and are not associated with DoIT’s privacy and use policies. After selecting a translation option, users will be notified that they are leaving DoIT’s website. Users should consult the original English content on DoIT’s website if there are any questions about the translated content.

    DoIT uses Google Translate to provide language translations of its content. Google Translate is a free, automated service that relies on data and technology to provide its translations. The Google Translate feature is provided for informational purposes only. Translations cannot be guaranteed as exact or without the inclusion of incorrect or inappropriate language. Google Translate is a third-party service and site users will be leaving DoIT to utilize translated content. As such, DoIT does not guarantee and does not accept responsibility for, the accuracy, reliability, or performance of this service nor the limitations provided by this service, such as the inability to translate specific files like PDFs and graphics (e.g. .jpgs, .gifs, etc.).

    DoIT provides Google Translate as an online tool for its users, but DoIT does not directly endorse the website or imply that it is the only solution available to users. All site visitors may choose to use alternate tools for their translation needs. Any individuals or parties that use DoIT content in translated form, whether by Google Translate or by any other translation services, do so at their own risk. DoIT is not liable for any loss or damages arising out of, or issues related to, the use of or reliance on translated content. DoIT assumes no liability for any site visitor’s activities in connection with use of the Google Translate functionality or content.

    The Google Translate service is a means by which DoIT offers translations of content and is meant solely for the convenience of non-English speaking users of the website. The translated content is provided directly and dynamically by Google; DoIT has no direct control over the translated content as it appears using this tool. Therefore, in all contexts, the English content, as directly provided by DoIT is to be held authoritative.

    Medicaid, HealthChoice MCOs take steps to prevent opioid-related problems

    Response follows treatment reimbursement boost in program’s renewed waiver

    Baltimore, MD (February 8, 2017) – In keeping with the Hogan administration’s leadership in fighting the opioid crisis in Maryland, the Department of Health and Mental Hygiene is announcing policies reforming the opioid-prescribing process in the Medicaid program, to seek to block the prescription pathway to substance use disorders.
    In partnership with all eight of its HealthChoice managed care organizations, the program Maryland Medicaid aims to reduce opioid misuse, dependence, overdose and death in both Medicaid fee-for-service and HealthChoice managed care programs.
    “These policy changes will not only help those struggling with substance abuse, but also aid prevention efforts, treatment options, and increase our capacity to save lives,” said Maryland Gov. Larry Hogan. “Our administration strongly supported Medicaid’s waiver renewal, which will significantly expand treatment options by providing reimbursement where it has been absent – and we support this step as well.”
    “More than 20 percent of Marylanders are enrolled in the HealthChoice program,” said Health and Mental Hygiene Secretary Dennis R. Schrader. “Six out of eight of our HealthChoice managed care organizations are integrated provider and payer networks, so they are natural partners in our efforts to combat the opioid epidemic. These changes support our strategic approach to enhance the reach of these policies through collaborative education, prevention and treatment action.”
    The policy changes, which will be in place by July 1, 2017, aim to:
    • Prevent medical and non-medical opioid use, abuse, and substance use disorder from developing;
    • Identify and treat opioid dependence early in the course of the disease;
    • Prevent overdose deaths, medical complications, psychosocial deterioration, transition to injection drug use, and injection-related disease; and
    • Identify and outreach to providers who do not follow standard practice.
    All high-dose and long-acting opioids, including fentanyl prescriptions issued to Maryland Medicaid members, are now subject to prior authorization. In addition to these new prior authorization requirements, Maryland Medicaid is also encouraging providers to:
    • Consider non-opioids as first-line treatment for chronic pain;
    • Offer naloxone to patients who meet certain risk factors;
    • Conduct thorough substance use disorder screening prior to prescribing opioids;
    • Refer patients to treatment that are identified as having a substance use disorder; and
    • Use the Department’s Prescription Drug Monitoring Program for all Controlled Dangerous Substance prescriptions.
    “We are united in this effort,” said Public Health Services Deputy Secretary Dr. Howard Haft. “We applaud the efforts that our state’s Medicaid program and its managed care organizations are embarking upon to tackle this nationwide crisis. The opioid epidemic is a serious public health threat. By improving prescribing practices, providers stand to help make marked progress in combatting the effects of the opioid epidemic in Maryland.”